CTOs on the Move

Inceptor Bio

www.inceptor.bio

 
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Inceptor Bio raised $37.7M on 03/04/2022

Similar Companies

Brain TunnelGenix Technologies Corp

Brain TunnelGenix Technologies Corp is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Manifold Bio

A next-generation protein therapeutics company pioneering an in vivo biologics design platform. By redesigning in vivo measurement to be available from day one, Manifold Bio has an advantage in solving complex biologic challenges.

Tgs Technologies

Tgs Technologies, Llc is a Cranberry Twp, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United States Biological Corporation

United States Biological Corporation is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.